Clinical Trial: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07357415) titled 'A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight' on Jan. 16.

Brief Summary: The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: Obesity Overweight

Intervention: DRUG: Retatrutide

Administered SC

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Company

Disclaimer: Curated by HT Syndication....